IRICoR has a very flexible business model adapted to the needs of the private sector that aims at de-risking the discovery and commercialization of proprietary paradigm-shifting therapeutic approaches in oncology, immunology and related indications. IRICoR’s model is based on four (4) main pillars.
Click the icons to view the contents
All platforms are managed by scientists with industry expertise who ensure professional supervision and continuous development of the technology platforms through partnerships with selected providers and key internal technology developers.
IRICoR’s value-added process is based on identification, support and management of high-potential projects with a clear path towards commercialization. This process is advantageously complemented by dedicated intellectual property (IP) building activities.
IRICoR develops IP strategies aimed at generating high quality IP assets with a clear path towards clinical development and market potential. This includes proprietary compounds identified by proprietary enabling tools as well as animal models for the establishment of pre-clinical proof of concept.
Existing IP, including know- how developed by IRIC/UdeM scientists, belongs to and is controlled by UdeM (through IRICoR as its authorized agent, according to Politique de l’UdeM sur la propriété intellectuelle). For novel IP generated jointly by IRIC/UdeM scientists and a collaborator’s personnel during the course of an IRICoR- funded project, UdeM and the collaborator (institution or company) are co-applicants on the related patent applications.
IP protection is mainly done through patenting but unregistered assets such as know-how linked to methods and cell/in vivo models are valued as well for an additional competitive edge.
IRICoR has the flexibility to continue prosecution of UdeM Background IP alone or with industry partners if there is mutual interest, thus keeping the possibility to maintain its position and be able to strategically grant non-exclusive licenses on the matter.
In order to crystallize the commercialization potential of its project portfolio, IRICoR devises exit strategies for each project to maximize its return on investment.
For additional information on IRICoR
T +514 343-6111 #30361
info@iricor.ca
For partnership and licensing opportunities
Steven J. Klein, PhD, MBA
Vice-President of Business Development
T +514 343‑6647
steven.klein@iricor.ca
Postal address
IRICoR
C.P. 6128, Downtown station
Montreal (Quebec) H3C 3J7
CANADA
Express Courier
IRICoR
Pavilion Marcelle-Coutu
2950, chemin de Polytechnique
Montreal (Quebec) H3T 1J4
The Oncopole and IRICoR have joined forces to launch the Scholarship Competition – Entrepreneurship in Oncology (CEO), offering the next generation of scientists an opportunity to develop their entrepreneurial skills, along with their academic skills. Thus, both organizations will offer training scholarships, as part of the new Life Sciences Entrepreneurship Development Program, created through a partnership between Montréal InVivo, Université de Montréal’s Faculty of Pharmacy and Concordia University’s John Molson Executive Centre, in collaboration with IRICoR.
This practical and immersive training, the result of a joint effort between key players in life sciences from both industry and academia, will allow you to familiarize yourself with the development stages of an innovative company, from the lab to the market, through current management models that apply to both the research and the commercialization of innovation stages.
For more information, go to:
The Oncopole and IRICoR want to ensure the training of the next generation of scientists through better tools for project management and entrepreneurial skills. Both organizations aim to identify the most promising candidates in the ecosystem and make it easier for them to get a training that meets their needs.
PhD candidates (at least 3 years completed), Postdoctoral Fellows and Young Investigators (Research Scholars – Junior 1 and Junior 2) (prior to tenure) affiliated with a Canadian teaching or research institution at application submission, are eligible.
The scholarship amount awarded to each recipient will cover the full program registration fees, namely $5,890 + taxes. Furthermore, applicants residing outside the Montreal metropolitan area could be reimbursed for part of their travel and accommodation costs related to having participated in the program.
Applicants must fill out the form (attached or below) and send it to audrey.segret@umontreal.ca, by February 7, 2018, at 5:00pm. The applicants can also contact Audrey for any question on the competition.
Applicants will be informed of the results by March 1, 2018. Applications will be assessed according to the following scorecard:
| Scoring | Sections | Criteria |
| – | 1. Applicant information | – |
| 15% | 2. Research experience: 50 words – Relevance of the oncology research project 100 words – Academic distinction 100 words – Scientific communication |
Activities and achievements to date |
| 35% | 3. Previous entrepreneurial experience: 300 words – Relevance of previous entrepreneurial experience (3 max.) 500 words – Demonstration of the applicant’s sense of entrepreneurship |
General characteristics and skills
Entrepreneurial experience and skills demonstrated |
| 50% | 4. Motivation: 500 words – Motivation to join the program 250 words – Expectations with respect to the program |
Potential shown
Alignment of program/career goals |
By submitting his/her application, the applicant must agree:
For more information about the Life Sciences Entrepreneurship Development Program, please contact:
Valérie Lancelot-Mingot
Programs Manager
John Molson School of Business
514 848-3960
valerie.lancelot-mingot@concordia.ca
About the Oncopole
The Oncopole is Quebec’s hub for research, development and investment to accelerate the fight against cancer. Created in February of 2017, it is the product of a unique co-creation process led by the Fonds de recherche du Québec – Santé (FRQS) and made possible by an initial $15M investment from Merck Canada. The Oncopole’s mission is to act as a catalyst leveraging actions made by the key players in Quebec’s oncology and innovation research ecosystem. As a result, it aims to position the province as a leader in the field. Its priorities of action, namely research, entrepreneurship, commercialization and integration of innovation, as well as clinical relevance, are orchestrated in order to foster the mobilization of stakeholders, the discovery of innovative approaches to fight cancer and, ultimately, a positive impact for the benefit of patients. For more information about Oncopole, go to: oncopole.ca
About the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR)
As Université de Montréal’s drug discovery and project maturation cluster, IRICoR is a not-for-profit organization based at the Institute for Research in Immunology and Cancer (IRIC), with the mandate to accelerate the discovery, development and commercialization of novel therapies in cancer, immunotherapy and related fields. Since its creation in 2008, IRICoR successfully invests in and supports cutting-edge projects with disruptive potential to rapidly translate innovation into patient-accessible therapies, through either co-development partnerships with industry or company creation. IRICoR seamlessly integrates business-related expertise with industry-level drug discovery in a world-renowned research institute, providing academics with access to a full drug discovery chain with one of the largest academia-based medicinal chemistry groups in Canada. For more information about IRICoR, go to: iricor.ca
The Oncopole and IRICoR have joined forces to launch the Scholarship Competition – Entrepreneurship in Oncology (CEO), offering the next generation of scientists an opportunity to develop their entrepreneurial skills, along with their academic skills. Thus, both organizations will offer training scholarships, as part of the new Life Sciences Entrepreneurship Development Program, created through a partnership between Montréal InVivo, Université de Montréal’s Faculty of Pharmacy and Concordia University’s John Molson Executive Centre, in collaboration with IRICoR.
This practical and immersive training, the result of a joint effort between key players in life sciences from both industry and academia, will allow you to familiarize yourself with the development stages of an innovative company, from the lab to the market, through current management models that apply to both the research and the commercialization of innovation stages.
For more information, go to:
The Oncopole and IRICoR want to ensure the training of the next generation of scientists through better tools for project management and entrepreneurial skills. Both organizations aim to identify the most promising candidates in the ecosystem and make it easier for them to get a training that meets their needs.
PhD candidates, Postdoctoral Fellows and Young Investigators (max 10 years in position) affiliated with a Canadian teaching or research institution, at the time of application submission, are eligible.
The scholarship amount awarded to each recipient will cover the full program registration fees, namely $5,890 + taxes. Furthermore, applicants residing outside the Montreal metropolitan area could be reimbursed for part of their travel and accommodation costs related to having participated in the program.
Applicants must fill out the form (attached or below) and send it to audrey.segret@umontreal.ca, by November 23rd 2018, at 5:00pm. The applicants can also contact Audrey for any question on the competition.
Applicants will be informed of the results by December 13th, 2018. Applications will be assessed according to the following scorecard:
| Scoring | Sections | Criteria |
| – | 1. Applicant information | – |
| 15% | 2. Research experience: 100 words – Relevance of your research project or your career to oncology100 words – Academic distinction100 words – Scientific communication |
Activities and achievements to date |
| 35% | 3. Previous entrepreneurial experience: 300 words – Relevance of previous entrepreneurial experience (3 max.) 500 words – Demonstration of the applicant’s sense of entrepreneurship |
General characteristics and skills
Entrepreneurial experience and skills demonstrated |
| 50% | 4. Motivation: 500 words – Motivation to join the program 250 words – Expectations with respect to the program |
Potential shown
Alignment of program/career goals |
By submitting his/her application, the applicant must agree:
For more information about the Life Sciences Entrepreneurship Development Program, please contact:
Valérie Lancelot-Mingot
Programs Manager
John Molson School of Business
514 848-3960
valerie.lancelot-mingot@concordia.ca
Description of the competition and its promoters
IRICoR and the Oncopole, in partnership with the FRQS, are launching the new LeadAction-Onco Competition. This joint call for projects is an opportunity for researchers from Quebec and the rest of Canada to accelerate the transformation of their projects in oncology and immuno-oncology into novel therapies for the benefit of patients.
Project eligibility
The researchers are invited to submit research projects that meet the following criteria:
Competition total budget: $2.4 M
Grant amount per project: maximum of $600,000 for 2 years.
Co-funding is not mandatory.
Important dates
Deadline for submitting the Notice of Intent: October 30, 2018, by 4:30 pm
Deadline for submitting the Complete Application: February 4, 2019, by 4:30 pm
Access the competition guidelines
For more information, please contact the following persons:
The Institute for Research in Immunology and Cancer — Commercialization of Research (IRICoR) is a not-for-profit drug discovery and commercialization centre based at the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal (UdeM). In 2008, the shared vision of IRIC’s scientists and the UdeM administration led to the creation of IRICoR. The Center was awarded an initial funding of $15M by the Government of Canada as a Centre of Excellence for Commercialization and Research (CECR).
IRICoR’s main objective is to rapidly translate highly innovative scientific projects from IRIC, UdeM and collaborating centres into high value novel therapies in oncology, immunology and related indications through strong partnerships with the private sector — thereby efficiently bridging the innovation translation gap between early stage academic research and industry.
IRICoR is a fully-integrated drug discovery and commercialization centre under a single roof, with one of the largest industry-experienced academia-based medicinal chemistry groups in Canada.
Embedded in a world-renowned research institute with key opinion leaders as principal investigators
Dr. Nadine Beauger, recently appointed Chief Executive Officer at IRICoR, was previously Vice-President – Scientific Liaison (intellectual property, academia-industry relations) at that same organization that she joined in 2009. Nadine led strategic IP portfolio management at IRICoR where she was instrumental at managing the IP budget, building and implementing the strategy for portfolio patent families which have led to successful licensing agreements. Dr. Beauger has brought to IRICoR over 15 years of experience in technology assessment and transfer, venture capital, intellectual property and project portfolio management, due diligence, and clinical and biotechnological research with thorough experience in both the private and the academic sectors.
Nadine began her career as a Patent Consultant at Robic, a Montreal-based IP boutique, where she undertook drafting, prosecution and IP strategic management of biotechnology patent applications. She went on as Associate at VantagePoint Venture Partners, a leading California headquartered venture capital firm. Just prior to joining IRICoR, Dr. Beauger was Manager, Business Development at Paladin Labs Inc, a top specialty pharmaceutical company based in Montreal.
She holds a Ph.D. in Biomedical Sciences (Hematology and Oncology), a M.Sc. in Cellular Biopathology from Université de Montréal and a B.Sc. in Anatomy from McGill University. She also holds an MBA degree from HEC Montréal (Excellence Studentship Award and Best Speaker Award). Dr. Beauger is a member of the Association of University Transfer Managers (AUTM).
Dr. Nadine Beauger, recently appointed Chief Executive Officer at IRICoR, was previously Vice-President – Scientific Liaison (intellectual property, academia-industry relations) at that same organization that she joined in 2009. Nadine led strategic IP portfolio management at IRICoR where she was instrumental at managing the IP budget, building and implementing the strategy for portfolio patent families which have led to successful licensing agreements. Dr. Beauger has brought to IRICoR over 15 years of experience in technology assessment and transfer, venture capital, intellectual property and project portfolio management, due diligence, and clinical and biotechnological research with thorough experience in both the private and the academic sectors.
Nadine began her career as a Patent Consultant at Robic, a Montreal-based IP boutique, where she undertook drafting, prosecution and IP strategic management of biotechnology patent applications. She went on as Associate at VantagePoint Venture Partners, a leading California headquartered venture capital firm. Just prior to joining IRICoR, Dr. Beauger was Manager, Business Development at Paladin Labs Inc, a top specialty pharmaceutical company based in Montreal.
She holds a Ph.D. in Biomedical Sciences (Hematology and Oncology), a M.Sc. in Cellular Biopathology from Université de Montréal and a B.Sc. in Anatomy from McGill University. She also holds an MBA degree from HEC Montréal (Excellence Studentship Award and Best Speaker Award). Dr. Beauger is a member of the Association of University Transfer Managers (AUTM).
→
Dr. Steven Klein is IRICoR’s Vice President of Business Development, with over 15 years of experience in a variety of fields, including oncology, immunology, and CNS-related indications. Prior to joining IRICoR, Dr. Klein held Business Development positions at Labopharm, BELLUS Health, Neurochem, and the Canadian Network for Vaccines and Immunotherapeutics (CANVAC). During his career, Dr. Klein negotiated and concluded a wide range of licensing and co-development agreements, covering both products and technologies, with industry leaders such as Pfizer, Bristol-Myers Squibb, Merck, Roche, GSK, Domain Therapeutics, Grunenthal, and Nippon Shinyaku.
Dr. Klein holds a B.Sc. (Honors) in Chemistry from Concordia University, a Ph.D. in Experimental Medicine from McGill University, and an MBA from Queen’s University. Dr. Klein is also a Board member of the Centre for the Commercialization of Antibodies and Biologics.
Dr. Steven Klein is IRICoR’s Vice President of Business Development, with over 15 years of experience in a variety of fields, including oncology, immunology, and CNS-related indications. Prior to joining IRICoR, Dr. Klein held Business Development positions at Labopharm, BELLUS Health, Neurochem, and the Canadian Network for Vaccines and Immunotherapeutics (CANVAC). During his career, Dr. Klein negotiated and concluded a wide range of licensing and co-development agreements, covering both products and technologies, with industry leaders such as Pfizer, Bristol-Myers Squibb, Merck, Roche, GSK, Domain Therapeutics, Grunenthal, and Nippon Shinyaku.
Dr. Klein holds a B.Sc. (Honors) in Chemistry from Concordia University, a Ph.D. in Experimental Medicine from McGill University, and an MBA from Queen’s University. Dr. Klein is also a Board member of the Centre for the Commercialization of Antibodies and Biologics.
→
Since joining IRICoR in 2009 as Project Manager, Alix Molinier has been responsible of the financial and administrative tasks, monitoring IRICoR’s portfolio projects. She also actively contributes to the development of follow-up and analysis tools for internal uses, and to the gathering of competitive intelligence around portfolio projects.
Ms. Molinier has over 12 years of experience in project management, with a specific focus on biotechnology start-up companies both from a scientific and a human resource standpoint. Alix began her career as an Analyst and Project Officer at Grand Luminy Incubator, a Marseille-based strategic support and logistics facility that assists in the creation of biotechnology businesses, where she undertook competitive intelligence analysis for the organization’s clients. She continued performing competitive intelligence analysis as an Analyst at CEIM (Centre d’entreprises et d’innovation de Montréal), an incubator of new technology companies. Just prior to joining IRICoR, she was Project Officer at Pharmabio Development, a Work Force sectoral Committee for pharmaceutical and biotechnology companies.
Ms. Molinier led her Engineering and Master II curricula in parallel. She holds a double Diploma in Project Management specializing in Biotechnology from Euromed Marseille – Management School and from ESIL (École Supérieure d’Ingénieurs de Luminy).
Since joining IRICoR in 2009 as Project Manager, Alix Molinier has been responsible of the financial and administrative tasks, monitoring IRICoR’s portfolio projects. She also actively contributes to the development of follow-up and analysis tools for internal uses, and to the gathering of competitive intelligence around portfolio projects.
Ms. Molinier has over 12 years of experience in project management, with a specific focus on biotechnology start-up companies both from a scientific and a human resource standpoint. Alix began her career as an Analyst and Project Officer at Grand Luminy Incubator, a Marseille-based strategic support and logistics facility that assists in the creation of biotechnology businesses, where she undertook competitive intelligence analysis for the organization’s clients. She continued performing competitive intelligence analysis as an Analyst at CEIM (Centre d’entreprises et d’innovation de Montréal), an incubator of new technology companies. Just prior to joining IRICoR, she was Project Officer at Pharmabio Development, a Work Force sectoral Committee for pharmaceutical and biotechnology companies.
Ms. Molinier led her Engineering and Master II curricula in parallel. She holds a double Diploma in Project Management specializing in Biotechnology from Euromed Marseille – Management School and from ESIL (École Supérieure d’Ingénieurs de Luminy).
→
Audrey Segret joined IRICoR in 2015 as Project Manager, and her responsibilities include tasks such as recruiting innovative scientific projects for potential investment, and regularly following up and reporting the progress of portfolio projects according to their milestones. She has also developed key analytics tools for project management within the organization.
Dr. Segret brings over 8 years of experience in project management to IRICoR. Prior to joining IRICoR, she contributed to business development activities at Boralex by ensuring coordination with internal departments (development, regulatory affairs, financial and operations on sites), executive level and partners. Prior to joining Boralex, Audrey was a scientific consultant at Alma Consulting Group (France and Canada) where she was in charge of managing a portfolio of clients involved in a number of research and development activities. For each project, she identified ways to secure a claim process (SR&ED) and to review reports submitted to government institutions. Audrey provided scientific and financial support to more than 200 innovative business projects.
Dr. Segret holds a Ph.D. in Life Sciences (speciality: cardiovascular pharmacology) and her research project was realized in the UMR-CNRS 8162 Unit (Paris V – France) on the «Implication of the CXCL12 chimiokine and its CXCR4 and CXCR7 receptors in cardiac physiology and physiopathology».
Audrey Segret joined IRICoR in 2015 as Project Manager, and her responsibilities include tasks such as recruiting innovative scientific projects for potential investment, and regularly following up and reporting the progress of portfolio projects according to their milestones. She has also developed key analytics tools for project management within the organization.
Dr. Segret brings over 8 years of experience in project management to IRICoR. Prior to joining IRICoR, she contributed to business development activities at Boralex by ensuring coordination with internal departments (development, regulatory affairs, financial and operations on sites), executive level and partners. Prior to joining Boralex, Audrey was a scientific consultant at Alma Consulting Group (France and Canada) where she was in charge of managing a portfolio of clients involved in a number of research and development activities. For each project, she identified ways to secure a claim process (SR&ED) and to review reports submitted to government institutions. Audrey provided scientific and financial support to more than 200 innovative business projects.
Dr. Segret holds a Ph.D. in Life Sciences (speciality: cardiovascular pharmacology) and her research project was realized in the UMR-CNRS 8162 Unit (Paris V – France) on the «Implication of the CXCL12 chimiokine and its CXCR4 and CXCR7 receptors in cardiac physiology and physiopathology».
→
Julie Simard Mercier joined IRICoR in 2014 as Intellectual Property Analyst. She participates in the blooming of IRIC’s IP assets by being actively involved in each of IRICoR’s IP-generating portfolio projects. She closely monitors the creation of new IP during the projects’ development and ensures that the protection strategy is well aligned with the commercialization plan.
She is also responsible for IRICoR’s IP portfolio management and prosecution, providing patentability opinions and contributing to the development of a specific filing strategy for each project, while also monitoring competing and complementary technologies’ development from an IP standpoint and a market outlook. Ms Simard Mercier has actively contributed to the expansion of IRICoR’s IP portfolio and to the partner readiness of the projects.
Ms Simard Mercier brings to IRICoR a broad IP expertise from her years at Norton Rose Fulbright LLP as a technical advisor. Her work focused on patent prosecution, opinion work and litigation technical support in the area of medicinal chemistry, pharmaceuticals and biotechnology. She holds a M. Sc. in Chemistry and a B. Sc. in Biopharmaceutical Sciences with a specialty in Medicinal Chemistry. During her undergraduate studies, she acquired valuable experience in the pharmaceutical industry by working at Bristol-Myers Squibb and GeminX Biotechnologies as a medical chemist.
Julie Simard Mercier joined IRICoR in 2014 as Intellectual Property Analyst. She participates in the blooming of IRIC’s IP assets by being actively involved in each of IRICoR’s IP-generating portfolio projects. She closely monitors the creation of new IP during the projects’ development and ensures that the protection strategy is well aligned with the commercialization plan.
She is also responsible for IRICoR’s IP portfolio management and prosecution, providing patentability opinions and contributing to the development of a specific filing strategy for each project, while also monitoring competing and complementary technologies’ development from an IP standpoint and a market outlook. Ms Simard Mercier has actively contributed to the expansion of IRICoR’s IP portfolio and to the partner readiness of the projects.
Ms Simard Mercier brings to IRICoR a broad IP expertise from her years at Norton Rose Fulbright LLP as a technical advisor. Her work focused on patent prosecution, opinion work and litigation technical support in the area of medicinal chemistry, pharmaceuticals and biotechnology. She holds a M. Sc. in Chemistry and a B. Sc. in Biopharmaceutical Sciences with a specialty in Medicinal Chemistry. During her undergraduate studies, she acquired valuable experience in the pharmaceutical industry by working at Bristol-Myers Squibb and GeminX Biotechnologies as a medical chemist.
→
Jonathan joined IRICoR as a Senior Advisor in April 2015 and brings experience in fundamental life-science research and diagnostic development. He is the Executive director of the Genome Canada-Quebec sponsored Leucegene Project, where he acts as the commercial lead, overseeing strategy and implementation. Prior to joining IRICoR, he held a CIHR Postdoctoral Fellowship at the University of Montreal, Institute for Research in Immunology and Cancer, where he was responsible for developing small molecule modulators of normal and leukemia stem cell growth.
Jonathan received his BSc from the Department of Microbiology and Immmunology and his PhD from the Department of Medicine at McGill University. In 2016, he will obtain an MBA from the John Molson School of Business at Concordia University. He is also a co-founding member of a medical device start-up company in orthopedic trauma.
Jonathan joined IRICoR as a Senior Advisor in April 2015 and brings experience in fundamental life-science research and diagnostic development. He is the Executive director of the Genome Canada-Quebec sponsored Leucegene Project, where he acts as the commercial lead, overseeing strategy and implementation. Prior to joining IRICoR, he held a CIHR Postdoctoral Fellowship at the University of Montreal, Institute for Research in Immunology and Cancer, where he was responsible for developing small molecule modulators of normal and leukemia stem cell growth.
Jonathan received his BSc from the Department of Microbiology and Immmunology and his PhD from the Department of Medicine at McGill University. In 2016, he will obtain an MBA from the John Molson School of Business at Concordia University. He is also a co-founding member of a medical device start-up company in orthopedic trauma.
→
Lizanne Boily joined IRICoR in 2015 as IRICoR’s administrative assistant. Prior to joining IRICoR, Lizanne worked at Versant Partners, a boutique investment bank specialized in biotechnology, which offered equity underwriting, private placement, and mergers and acquisitions advisory services. During that time, she contributed to the support in the administration of project management, accounting, human resources and compliance. She also worked as executive assistant to the Research Director at National Bank Financial and as a laboratory technician in chemistry at both universities and private companies. With more than 20 years of experience in the financial sector, Lizanne brings her knowledge in facilitating the coordination and implementation of different administrative tasks and responsibilities and ensures work efficiency among team members.
Lizanne holds a Bachelor degree in Sciences from Université de Montréal, a certification in Human Resources Management at HEC, and a Canadian Securities Course certification.
Lizanne Boily joined IRICoR in 2015 as IRICoR’s administrative assistant. Prior to joining IRICoR, Lizanne worked at Versant Partners, a boutique investment bank specialized in biotechnology, which offered equity underwriting, private placement, and mergers and acquisitions advisory services. During that time, she contributed to the support in the administration of project management, accounting, human resources and compliance. She also worked as executive assistant to the Research Director at National Bank Financial and as a laboratory technician in chemistry at both universities and private companies. With more than 20 years of experience in the financial sector, Lizanne brings her knowledge in facilitating the coordination and implementation of different administrative tasks and responsibilities and ensures work efficiency among team members.
Lizanne holds a Bachelor degree in Sciences from Université de Montréal, a certification in Human Resources Management at HEC, and a Canadian Securities Course certification.
→
Under revision.
Under revision.
IRICoR’s strategy focuses on leveraging the Centre’s deep scientific and business knowledge in oncology and related fields to select and invest in highly innovative projects thus filling the Innovation Translation Gap and accelerating the commercialization of cutting-edge products.
To capture and maximize the value of cutting edge research through translation of innovative academic discovery into new therapies
To accelerate the discovery and commercialization of novel highly innovative therapies in oncology and related indications by establishing strong partnerships with industry
